1 Study Matches
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)
Repotrectinib for cancer that has returned or is not responding to treatment
If you agree to take part in this study, you will need to visit the study site regularly and follow the study procedures listed later in this document. You will be told what these procedures are and why they are needed. These procedures include interviews, exams, heart testing, tumor assessments, and blood and urine samples. You will be asked to take the study drug Repotrectinib. This is a capsule to be taken orally.
Suzanne Treadway - at firstname.lastname@example.org or 717-531-3097
Inclusion Criteria:You have cancer that has returned or is not respondin g to treatment
You are positive for certain changes in your genes which we will test you for as needed
Exclusion Criteria:1. You have gastrointestinal disease, such as Crohn’s disease,